First report of secondary metabolites, Violaceol I and Violaceol II produced by endophytic fungus, Trichoderma polyalthiae and their antimicrobial activity

Nuankeaw, Katesaraporn; Chaiyosang, Boonyanoot; Suebrasri, Thanapat; Kanokmedhakul, Somdej; Lumyong, S.; Boonlue, Sophon

doi:10.1016/j.myc.2019.10.001

Cited by 29 publications

(16 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A chemical investigation of the endophytic fungus T. polyalthiae offered two diphenyl ethers, Violaceol I (200) and II (201). Notably, both of them were characterized from Trichoderma for the first time (Nuankeaw et al, 2020). Trichodenols A (202) and B (203), two new compounds with 4-(2-hydroxyethyl) phenol moieties, were isolated from an endophyte T. gamsii (Ding et al, 2015).…”

Section: Other Compoundsmentioning

confidence: 99%

Trichoderma: A Treasure House of Structurally Diverse Secondary Metabolites With Medicinal Importance

Zhang

Tang²,

Huang

et al. 2021

Front. Microbiol.

View full text Add to dashboard Cite

Fungi play an irreplaceable role in drug discovery in the course of human history, as they possess unique abilities to synthesize diverse specialized metabolites with significant medicinal potential. Trichoderma are well-studied filamentous fungi generally observed in nature, which are widely marketed as biocontrol agents. The secondary metabolites produced by Trichoderma have gained extensive attention since they possess attractive chemical structures with remarkable biological activities. A large number of metabolites have been isolated from Trichoderma species in recent years. A previous review by Reino et al. summarized 186 compounds isolated from Trichoderma as well as their biological activities up to 2008. To update the relevant list of reviews of secondary metabolites produced from Trichoderma sp., we provide a comprehensive overview in regard to the newly described metabolites of Trichoderma from the beginning of 2009 to the end of 2020, with emphasis on their chemistry and various bioactivities. A total of 203 compounds with considerable bioactivities are included in this review, which is worth expecting for the discovery of new drug leads and agrochemicals in the foreseeable future. Moreover, new strategies for discovering secondary metabolites of Trichoderma in recent years are also discussed herein.

show abstract

Section: Other Compoundsmentioning

confidence: 99%

Trichoderma: A Treasure House of Structurally Diverse Secondary Metabolites With Medicinal Importance

Zhang

Tang²,

Huang

et al. 2021

Front. Microbiol.

View full text Add to dashboard Cite

show abstract

“…Isocoumarins (111-120), dihydroisocoumarins (121)(122)(123)(124)(125)(126)(127), and other lactones (128-148) can be distinguished among cyclic esters. Most of the new and known metabolites can be assigned to phenols and their derivatives and diphenyl esters (177)(178)(179)(180)(181)(182)(183)(184)(185)(186)(187)(188)(189). Many isolated metabolites were aromatic compounds, i.e., phenalenones (190)(191)(192)(193)(194)(195)(196)(197)(198), grisane metabolites (199)(200)(201), and azaphilones .…”

Section: Other Polyketidesmentioning

confidence: 99%

“…The study of the secondary metabolites of a fungus of the Pseudopestalotiopsis genus [102] afforded the known polyketides, i.e., pesteic acid (177) and pestalotether A (178) [177]. The seafloor fungus Penicillium chrysogenum MCCC 3A00292 [46] produces a series of antibiotic polyketides of different natures, i.e., 3,3'-dihydroxy-5,5'-dimethyldiphenyl ether (183) [178], aspermutarubrol (184) also known as violaceol I [179,180], violaceol II (180) [180,181], and asperde-min (133) [163]. Screening of marine micromycetes for the antibacterial activity gave the producer strain of six known metabolites [74] including polyketide, methyl asterrate (182) [182,183].…”

Section: Other Polyketidesmentioning

confidence: 99%

See 1 more Smart Citation

Antibiotics from Extremophilic Micromycetes

et al. 2020

View full text Add to dashboard Cite

Extremophilic microorganisms, which are capable of functioning normally at extremely high or low temperatures, pressure, and in other environmental conditions, have been in the focus of microbiologists’ attention for several decades due to the biotechnological potential of enzymes inherent in extremophiles. These enzymes (also called extremozymes) are used in the production of food and detergents and other industries. At the same time, the inhabitants of extreme econiches remained almost unexplored for a long time in terms of the chemistry of natural compounds. In recent years, the emergence of new antibiotic-resistant strains of pathogens, which affect humans and animals has become a global problem. The problem is compounded by a strong slowdown in the development of new antibiotics. In search of new active substances and scaffolds for medical chemistry, researchers turn to unexplored natural sources. In recent years, there has been a sharp increase in the number of studies on secondary metabolites produced by extremophiles. From the discovery of penicillin to the present day, micromycetes, along with actinobacteria, are one of the most productive sources of antibiotic compounds for medicine and agriculture. Many authors consider extremophilic micromycetes as a promising source of small molecules with an unusual mechanism of action or significant structural novelty. This review summarizes the latest (for 2018–2019) experimental data on antibiotic compounds, which are produced by extremophilic micromycetes with various types of adaptation. Active metabolites are classified by the type of structure and biosynthetic origin. The data on the biological activity of the isolated metabolites are summarized.

show abstract

“…Strains in Trichoderma genus have been proved to produce a variety of biologically active compounds. The phenols violaceol I and violaceol II isolated from T. polyalthiae showed the antimicrobial activity against human pathogens with a broad spectrum [3] . Trichoderpyrone, a unique cyclopentenone–pyrone hybrid skeleton polyketide, isolated from a endophytic fungus Trichoderma gamsii , presented the weak cytotoxic activities against A549, HepG2, and HeLa cancer cells [4] .…”

Section: Introductionmentioning

confidence: 99%

Koninginin W, a New Polyketide from the Endophytic Fungus Trichoderma koningiopsis YIM PH30002

Wang

Qian

et al. 2021

Chemistry & Biodiversity

View full text Add to dashboard Cite

A new compound named koninginin W (1) and four known polyketides (2–5) were isolated from endophytic fungus Trichoderma koningiopsis YIM PH30002 of Panax notoginseng. The structures of 1 ‐ 5, including absolute configuration of 1, were elucidated on the detailed analysis of the HR‐ESI‐MS, 1D and 2D NMR, and X‐ray crystallographic data. Koninginin W (1) presented weak antibacterial activity against Escherichia coli, Bacillus subtilis and Salmonella typhimurium.

show abstract

First report of secondary metabolites, Violaceol I and Violaceol II produced by endophytic fungus, Trichoderma polyalthiae and their antimicrobial activity

Cited by 29 publications

References 24 publications

Trichoderma: A Treasure House of Structurally Diverse Secondary Metabolites With Medicinal Importance

Trichoderma: A Treasure House of Structurally Diverse Secondary Metabolites With Medicinal Importance

Antibiotics from Extremophilic Micromycetes

Koninginin W, a New Polyketide from the Endophytic Fungus Trichoderma koningiopsis YIM PH30002

Contact Info

Product

Resources

About